Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NewCardio's automated cardiac safety solution has been selected by a biotechnology pharmaceutical company focused on developing small molecule therapeutics for disorders of the central nervous system (CNS).
Subscribe to our email newsletter
The new solution, QTinno is intended to be used for an upcoming Thorough QT trial.
According to the company, QTinno 3-D ECG software technology is a novel, fully automated program for evaluating QT and other timing intervals relevant for assessing drug cardiac toxicity in drug development.
NewCardio COO Greg Sadowski said the company is pleased to participate in the TQT trial for a biotech company with their CRO partner.
"QTinno’s selection for this study, based on the performance in prior studies, provides clear evidence of the pharmaceutical company’s confidence, not only in the accuracy and precision of QTinno’s fully automated ECG analysis, but also in the FDA’s willingness to accept drug safety data from properly validated technology such as QTinno," Sadowski added.